Abciximab
Metamizole may increase the anticoagulant activities of Abciximab.
Acebutolol
Metamizole may decrease the antihypertensive activities of Acebutolol.
Aceclofenac
The risk or severity of adverse effects can be increased when Metamizole is combined with Aceclofenac.
Advertisement
Acemetacin
The risk or severity of adverse effects can be increased when Metamizole is combined with Acemetacin.
Acenocoumarol
Metamizole may increase the anticoagulant activities of Acenocoumarol.
Acetaminophen
The risk or severity of adverse effects can be increased when Metamizole is combined with Acetaminophen.
Advertisement
Acetyl salicylate
The risk or severity of adverse effects can be increased when Metamizole is combined with Acetylsalicylic acid.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Metamizole.
Ado-Trastuzumab Emtansine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Trastuzumab emtansine.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Alclometasone.
Aldesleukin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Aldesleukin.
Aldosterone
The risk or severity of adverse effects can be increased when Metamizole is combined with Aldosterone.
Alemtuzumab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Alemtuzumab.
Alendronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.
Aliskiren
Metamizole may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Alminoprofen.
Alprenolol
Metamizole may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Metamizole.
Altretamine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Altretamine.
Amcinonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Amcinonide.
Amikacin
Metamizole may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Metamizole may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Aminosalicylic Acid.
Amiodarone
Metamizole may decrease the antihypertensive activities of Amiodarone.
Amsacrine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Amsacrine.
Ancrod
Metamizole may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Metamizole is combined with Androstenedione.
Anhydrous Tacrolimus
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Metamizole is combined with Antipyrine.
Antithrombin III
Metamizole may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Metamizole may increase the anticoagulant activities of Antithrombin III human.
Apazone
The risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.
Apixaban
Metamizole may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Metamizole is combined with Apremilast.
Arbekacin
Metamizole may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Metamizole may increase the anticoagulant activities of Ardeparin.
Argatroban
Metamizole may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Metamizole may increase the anticoagulant activities of Argatroban.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.
Arsenic Trioxide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Arsenic trioxide.
Asenapine
Metamizole may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Metamizole is combined with Ginseng.
Aspirin
The risk or severity of adverse effects can be increased when Metamizole is combined with Acetylsalicylic acid.
Asunaprevir
The serum concentration of Asunaprevir can be decreased when it is combined with Metamizole.
Atenolol
Metamizole may decrease the antihypertensive activities of Atenolol.
Azacitidine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Azacitidine.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Metamizole.
azficel-T
The risk or severity of adverse effects can be increased when Metamizole is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Metamizole.
Balsalazide
The risk or severity of adverse effects can be increased when Metamizole is combined with Balsalazide.
Becaplermin
Metamizole may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Metamizole is combined with Beclomethasone dipropionate.
Belinostat
The risk or severity of myelosuppression can be increased when Metamizole is combined with Belinostat.
Benazepril
The risk or severity of adverse effects can be increased when Metamizole is combined with Benazepril.
Bendamustine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bendamustine.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Metamizole.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Metamizole.
Benzydamine
The risk or severity of adverse effects can be increased when Metamizole is combined with Benzydamine.
Betamethasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Betamethasone.
Betaxolol
Metamizole may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Metamizole.
Bevacizumab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bevacizumab.
Bevacizumab-Awwb
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bevacizumab.
Bexarotene
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bexarotene.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Metamizole.
Bisoprolol
Metamizole may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Metamizole may increase the anticoagulant activities of Bivalirudin.
Blinatumomab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Blinatumomab.
Bopindolol
Metamizole may decrease the antihypertensive activities of Bopindolol.
Bortezomib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bortezomib.
Bosutinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib.
Bosutinib monohydrate
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib.
Bromfenac
The risk or severity of adverse effects can be increased when Metamizole is combined with Bromfenac.
Budesonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Metamizole is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Metamizole.
Bupranolol
Metamizole may decrease the antihypertensive activities of Bupranolol.
Busulfan
The risk or severity of myelosuppression can be increased when Metamizole is combined with Busulfan.
Cabazitaxel
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cabazitaxel.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Metamizole.
Capecitabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Metamizole is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Metamizole is combined with Captopril.
Carbamazepine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Carbamazepine.
Carboplatin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Carboplatin.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole.
Carfilzomib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Carfilzomib.
Carmustine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Carmustine.
Carprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Carprofen.
Carteolol
Metamizole may decrease the antihypertensive activities of Carteolol.
Carvedilol
Metamizole may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Metamizole is combined with Celecoxib.
Celiprolol
Metamizole may decrease the antihypertensive activities of Celiprolol.
Certoparin
Metamizole may increase the anticoagulant activities of Certoparin.
Chlorambucil
The risk or severity of myelosuppression can be increased when Metamizole is combined with Chlorambucil.
Chloramphenicol
The risk or severity of myelosuppression can be increased when Metamizole is combined with Chloramphenicol.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Metamizole.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.
Chlorphenesin
The risk or severity of adverse effects can be increased when Metamizole is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Metamizole.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Metamizole is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Metamizole is combined with Cilazapril.
Cinoxacin
Metamizole may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Metamizole may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cisplatin.
Citric Acid
Metamizole may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Metamizole may increase the anticoagulant activities of Citric Acid.
Cladribine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cladribine.
Clobetasol
The risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Clodronic Acid.
Clofarabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Clofarabine.
Clonixin
The risk or severity of adverse effects can be increased when Metamizole is combined with Clonixin.
Colesevelam
Colesevelam can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Metamizole is combined with Cortisone acetate.
Curcumin
The risk or severity of adverse effects can be increased when Metamizole is combined with Curcumin.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Metamizole.
Cyclophosphamide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cyclophosphamide.
Cyclosporine
Metamizole may increase the nephrotoxic activities of Cyclosporine.
Cytarabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cytarabine.
Dabigatran Etexilate
Metamizole may increase the anticoagulant activities of Dabigatran etexilate.
Dacarbazine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dacarbazine.
Dactinomycin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dactinomycin.
Dalteparin
Metamizole may increase the anticoagulant activities of Dalteparin.
Danaparoid
Metamizole may increase the anticoagulant activities of Danaparoid.
Dasatinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dasatinib.
Dasatinib Anhydrous
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dasatinib.
Daunorubicin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Daunorubicin.
Decitabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Decitabine.
Deferasirox
The risk or severity of adverse effects can be increased when Metamizole is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Metamizole is combined with Deflazacort.
Desipramine
Metamizole may decrease the antihypertensive activities of Desipramine.
Desirudin
Metamizole may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Metamizole is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Metamizole is combined with Desoxycorticosterone Pivalate.
Dexamethasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metamizole.
Dexrazoxane
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dexrazoxane.
Dextran
Metamizole may increase the anticoagulant activities of Dextran.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole.
Dicumarol
Metamizole may increase the anticoagulant activities of Dicoumarol.
Diflorasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Metamizole is combined with Diflunisal.
Difluprednate
The risk or severity of adverse effects can be increased when Metamizole is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Metamizole.
Dihydrostreptomycin
Metamizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Metamizole.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Metamizole.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Metamizole.
Dinutuximab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dinutuximab.
Docetaxel
The risk or severity of myelosuppression can be increased when Metamizole is combined with Docetaxel.
DOCETAXEL ANHYDROUS
The risk or severity of myelosuppression can be increased when Metamizole is combined with Docetaxel.
Doxorubicin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Doxorubicin.
Doxorubicin Hydrochloride
The risk or severity of myelosuppression can be increased when Metamizole is combined with Doxorubicin.
Drospirenone
Metamizole may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Metamizole is combined with Droxicam.
Edetic Acid
Metamizole may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Metamizole may increase the anticoagulant activities of Edoxaban.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Metamizole is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Metamizole is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Metamizole is combined with Enalaprilat.
Enoxacin
Metamizole may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Metamizole may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Metamizole may increase the anticoagulant activities of Enoxaparin.
Epirubicin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Epirubicin.
Eplerenone
Metamizole may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Metamizole.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole.
Eribulin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Eribulin.
Esmolol
Metamizole may decrease the antihypertensive activities of Esmolol.
Estrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Metamizole is combined with Etanercept.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Metamizole.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Metamizole.
Ethylenediaminetetraacetate
Metamizole may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Metamizole is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Metamizole is combined with Etofenamate.
Etoposide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Etoposide.
Etoricoxib
The risk or severity of adverse effects can be increased when Metamizole is combined with Etoricoxib.
Evening primrose oil
The risk or severity of adverse effects can be increased when Metamizole is combined with Evening primrose oil.
Everolimus
The risk or severity of myelosuppression can be increased when Metamizole is combined with Everolimus.
Felbinac
The risk or severity of adverse effects can be increased when Metamizole is combined with Felbinac.
Fenbufen
The risk or severity of adverse effects can be increased when Metamizole is combined with Fenbufen.
Fenoprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Fenoprofen.
Ferulic Acid
Metamizole may increase the anticoagulant activities of Ferulic acid.
Fish Oils
The risk or severity of adverse effects can be increased when Metamizole is combined with Fish oil.
Fleroxacin
Metamizole may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Metamizole.
Floxuridine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Floxuridine.
Flucytosine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Flucytosine.
Fludarabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Fludarabine.
Fludrocortisone
The risk or severity of adverse effects can be increased when Metamizole is combined with Fludrocortisone.
Fluindione
Metamizole may increase the anticoagulant activities of Fluindione.
Flumequine
Metamizole may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Metamizole is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Metamizole is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluorometholone.
Fluorouracil
The risk or severity of myelosuppression can be increased when Metamizole is combined with Fluorouracil.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Metamizole is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Flurbiprofen.
Fluticasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone propionate.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Metamizole.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Metamizole.
Fondaparinux sodium
Metamizole may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Metamizole is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Metamizole is combined with Fosinopril.
Framycetin
Metamizole may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Metamizole.
Gatifloxacin
Metamizole may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Metamizole may increase the neuroexcitatory activities of Gatifloxacin.
Gemcitabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Gemcitabine.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Metamizole.
Gemifloxacin
Metamizole may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Metamizole may increase the neuroexcitatory activities of Gemifloxacin.
Gemtuzumab ozogamicin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Gemtuzumab ozogamicin.
Gentamicin
Metamizole may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Metamizole is combined with Ginseng.
Grepafloxacin
Metamizole may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Metamizole is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Metamizole is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.
Heparin
Metamizole may increase the anticoagulant activities of Heparin.
Hydralazine
Metamizole may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Metamizole.
Hydrocortisone
The risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Metamizole.
Hydroxyurea
The risk or severity of myelosuppression can be increased when Metamizole is combined with Hydroxyurea.
Ibandronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.
Ibritumomab Tiuxetan
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ibritumomab tiuxetan.
Ibrutinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ibrutinib.
Ibuprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant.
Idarubicin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Idarubicin.
Ifosfamide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ifosfamide.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Metamizole.
Imatinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Imatinib.
Imidapril
The risk or severity of adverse effects can be increased when Metamizole is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole.
Indobufen
The risk or severity of adverse effects can be increased when Metamizole is combined with Indobufen.
Indomethacin
The risk or severity of adverse effects can be increased when Metamizole is combined with Indomethacin.
Interferon Alfa-n3
The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-n3.
Interferon Alfacon-1
The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfacon-1.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.
Irinotecan
The risk or severity of myelosuppression can be increased when Metamizole is combined with Irinotecan.
Ixabepilone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ixabepilone.
Kanamycin
Metamizole may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Metamizole may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Metamizole is combined with Kebuzone.
Ketoprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Ketoprofen.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Metamizole.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Metamizole is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Metamizole is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Metamizole is combined with Ginseng.
Labetalol
Metamizole may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Metamizole.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Metamizole.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Metamizole.
Lenalidomide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Lenalidomide.
Lepirudin
Metamizole may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Metamizole may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Metamizole may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Metamizole may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Metamizole may increase the neuroexcitatory activities of Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when Metamizole is combined with (4R)-limonene.
Linezolid
The risk or severity of myelosuppression can be increased when Metamizole is combined with Linezolid.
Lisinopril
The risk or severity of adverse effects can be increased when Metamizole is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Metamizole is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Metamizole.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Metamizole.
Lomefloxacin
Metamizole may increase the neuroexcitatory activities of Lomefloxacin.
Lomustine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Lomustine.
Lornoxicam
The risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.
Loteprednol
The risk or severity of adverse effects can be increased when Metamizole is combined with Loteprednol.
Loxoprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Loxoprofen.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Metamizole.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Metamizole is combined with Magnesium salicylate.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Metamizole.
Mechlorethamine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Mechlorethamine.
Meclofenamate
The risk or severity of adverse effects can be increased when Metamizole is combined with Meclofenamic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Meclofenamic acid.
Medronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Metamizole is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Mefenamic acid.
Meloxicam
The risk or severity of adverse effects can be increased when Metamizole is combined with Meloxicam.
Melphalan
The risk or severity of myelosuppression can be increased when Metamizole is combined with Melphalan.
Mepindolol
Metamizole may decrease the antihypertensive activities of Mepindolol.
Mercaptopurine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Mercaptopurine.
MERCAPTOPURINE ANHYDROUS
The risk or severity of myelosuppression can be increased when Metamizole is combined with Mercaptopurine.
Mesalamine
The risk or severity of adverse effects can be increased when Metamizole is combined with Mesalazine.
Methimazole
The risk or severity of myelosuppression can be increased when Metamizole is combined with Methimazole.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Metamizole.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.
Methylprednisolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone.
Metipranolol
Metamizole may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.
Metoprolol
Metamizole may decrease the antihypertensive activities of Metoprolol.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Metamizole.
Mitomycin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Mitomycin.
Mitoxantrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Mitoxantrone.
Moexipril
The risk or severity of adverse effects can be increased when Metamizole is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Metamizole.
Moxifloxacin
Metamizole may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Metamizole.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.
Nabumetone
The risk or severity of adverse effects can be increased when Metamizole is combined with Nabumetone.
Nadolol
Metamizole may decrease the antihypertensive activities of Nadolol.
Nadroparin
Metamizole may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Metamizole.
Nalidixic Acid
Metamizole may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Metamizole is combined with Naproxen.
Nebivolol
Metamizole may decrease the antihypertensive activities of Nebivolol.
Nelarabine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Nelarabine.
Neomycin
Metamizole may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Metamizole is combined with Nepafenac.
Netilmicin
Metamizole may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Niflumic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Niflumic Acid.
Nilotinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Metamizole is combined with Nimesulide.
Norfloxacin
Metamizole may increase the neuroexcitatory activities of Norfloxacin.
Obinutuzumab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Obinutuzumab.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Metamizole is combined with Evening primrose oil.
Ofloxacin
Metamizole may increase the neuroexcitatory activities of Ofloxacin.
Olaparib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Metamizole.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.
Olsalazine
Metamizole may increase the nephrotoxic activities of Olsalazine.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Metamizole is combined with Omacetaxine mepesuccinate.
Oxaliplatin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Oxaliplatin.
Oxaprozin
The risk or severity of adverse effects can be increased when Metamizole is combined with Oxaprozin.
Oxprenolol
Metamizole may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole.
Paclitaxel
The risk or severity of myelosuppression can be increased when Metamizole is combined with Paclitaxel.
Palbociclib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Palbociclib.
Palmidrol
The risk or severity of adverse effects can be increased when Metamizole is combined with Palmidrol.
Pamidronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Metamizole is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Metamizole is combined with Parecoxib.
Paromomycin
Metamizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Parthenolide
The risk or severity of adverse effects can be increased when Metamizole is combined with Parthenolide.
Pefloxacin
Metamizole may increase the neuroexcitatory activities of Pefloxacin.
Peginterferon Alfa-2a
The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b
The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2b.
Pemetrexed
The risk or severity of myelosuppression can be increased when Metamizole is combined with Pemetrexed.
Penbutolol
Metamizole may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Metamizole may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Metamizole may increase the anticoagulant activities of Pentosan Polysulfate.
Pentostatin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Pentostatin.
Perindopril
The risk or severity of adverse effects can be increased when Metamizole is combined with Perindopril.
Phenindione
Metamizole may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Metamizole may increase the anticoagulant activities of Phenprocoumon.
Phenylalanine
The risk or severity of myelosuppression can be increased when Metamizole is combined with L-Phenylalanine.
Phenylbutazone
The risk or severity of adverse effects can be increased when Metamizole is combined with Phenylbutazone.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Metamizole.
Pindolol
Metamizole may decrease the antihypertensive activities of Pindolol.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Metamizole.
Pirfenidone
The risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone.
Piroxicam
The risk or severity of adverse effects can be increased when Metamizole is combined with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Metamizole is combined with Piroxicam.
Plazomicin
Metamizole may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Metamizole.
Pomalidomide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Pomalidomide.
Ponatinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ponatinib.
Potassium Citrate
Metamizole may increase the anticoagulant activities of Potassium Citrate.
Practolol
Metamizole may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Metamizole.
Prasterone
The risk or severity of adverse effects can be increased when Metamizole is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Metamizole is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Metamizole is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Pregnenolone.
Probenecid
The serum concentration of Metamizole can be increased when it is combined with Probenecid.
Procarbazine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Procarbazine.
Propafenone
Metamizole may decrease the antihypertensive activities of Propafenone.
Propranolol
Metamizole may decrease the antihypertensive activities of Propranolol.
Propylthiouracil
The risk or severity of myelosuppression can be increased when Metamizole is combined with Propylthiouracil.
protein C, human
Metamizole may increase the anticoagulant activities of Protein C.
protein S, human
Metamizole may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Metamizole may increase the anticoagulant activities of Protocatechualdehyde.
Quinapril
The risk or severity of adverse effects can be increased when Metamizole is combined with Quinapril.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Metamizole.
Raltitrexed
The risk or severity of myelosuppression can be increased when Metamizole is combined with Raltitrexed.
Ramipril
The risk or severity of adverse effects can be increased when Metamizole is combined with Ramipril.
Rescinnamine
The risk or severity of adverse effects can be increased when Metamizole is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Metamizole is combined with Resveratrol.
Reviparin
Metamizole may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Metamizole may increase the anticoagulant activities of Reviparin.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Metamizole.
Rimexolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.
Rituximab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Rituximab.
Rivaroxaban
Metamizole may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Metamizole is combined with Rofecoxib.
Rosoxacin
Metamizole may increase the neuroexcitatory activities of Rosoxacin.
Ruxolitinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ruxolitinib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Metamizole.
Salicylamide
The risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Salicylic acid.
Salsalate
The risk or severity of adverse effects can be increased when Metamizole is combined with Salsalate.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Metamizole.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Metamizole.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Metamizole.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Metamizole.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Metamizole is combined with Serrapeptase.
Sirolimus
The risk or severity of myelosuppression can be increased when Metamizole is combined with Sirolimus.
Sisomicin
Metamizole may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Metamizole may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Metamizole.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Metamizole.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Metamizole.
Sorafenib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Sorafenib.
Sotalol
Metamizole may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Metamizole may increase the neuroexcitatory activities of Sparfloxacin.
Spirapril
The risk or severity of adverse effects can be increased when Metamizole is combined with Spirapril.
Spironolactone
Metamizole may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Metamizole may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Streptozocin.
Sulfasalazine
The risk or severity of adverse effects can be increased when Metamizole is combined with Sulfasalazine.
Sulindac
The risk or severity of adverse effects can be increased when Metamizole is combined with Sulindac.
Suprofen
The risk or severity of adverse effects can be increased when Metamizole is combined with Suprofen.
Tacrolimus
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Metamizole.
Talinolol
Metamizole may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Metamizole.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Technetium Tc-99m medronate.
Tedizolid
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tedizolid Phosphate.
Tedizolid Phosphate
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tedizolid Phosphate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole.
Temafloxacin
Metamizole may increase the neuroexcitatory activities of Temafloxacin.
Temozolomide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Temozolomide.
Temsirolimus
The risk or severity of myelosuppression can be increased when Metamizole is combined with Temsirolimus.
Teniposide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Teniposide.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Metamizole is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Metamizole is combined with Tenoxicam.
Terbutaline
Metamizole may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Metamizole may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Metamizole is combined with Teriflunomide.
Tertatolol
Metamizole may decrease the antihypertensive activities of Tertatolol.
Thalidomide
The risk or severity of myelosuppression can be increased when Metamizole is combined with Thalidomide.
Thioguanine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tioguanine.
Thioguanine Anhydrous
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tioguanine.
Thiotepa
The risk or severity of myelosuppression can be increased when Metamizole is combined with Thiotepa.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Tiaprofenic acid.
Tiludronate
The risk or severity of adverse effects can be increased when Metamizole is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Tiludronic acid.
Timolol
Metamizole may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Metamizole may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Metamizole is combined with Tixocortol.
Tobramycin
Metamizole may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tofacitinib
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tofacitinib.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid.
Tolmetin
The risk or severity of adverse effects can be increased when Metamizole is combined with Tolmetin.
Topotecan
The risk or severity of myelosuppression can be increased when Metamizole is combined with Topotecan.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Metamizole.
Tositumomab
The risk or severity of myelosuppression can be increased when Metamizole is combined with Tositumomab.
Trabectedin
The risk or severity of myelosuppression can be increased when Metamizole is combined with Trabectedin.
Trandolapril
The risk or severity of adverse effects can be increased when Metamizole is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Metamizole.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole.
Triamcinolone
The risk or severity of adverse effects can be increased when Metamizole is combined with Triamcinolone.
Triamterene
Metamizole may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Metamizole is combined with Tribenoside.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Metamizole.
Trisodium Citrate Anhydrous
Metamizole may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Metamizole is combined with Trolamine salicylate.
Trovafloxacin
Metamizole may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Metamizole may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Metamizole.
Valdecoxib
The risk or severity of adverse effects can be increased when Metamizole is combined with Valdecoxib.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Metamizole.
Vinblastine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Vinblastine.
Vindesine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Vindesine.
Vinorelbine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Vinorelbine.
Vorinostat
The risk or severity of myelosuppression can be increased when Metamizole is combined with Vorinostat.
Warfarin
Metamizole may increase the anticoagulant activities of Warfarin.
Zidovudine
The risk or severity of myelosuppression can be increased when Metamizole is combined with Zidovudine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Metamizole.
Zofenopril
The risk or severity of adverse effects can be increased when Metamizole is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Metamizole is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Metamizole is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Metamizole is combined with Zomepirac.
